share_log

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives $45.83 Consensus Target Price From Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives $45.83 Consensus Target Price From Brokerages

費森尤斯醫療保健股份公司(紐約證券交易所市場代碼:FMS)從經紀公司獲得45.83美元的共識目標價
Financial News Live ·  2022/09/19 07:42

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) has earned a consensus recommendation of "Hold" from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $45.83.

據市場評級公司報道,Fresenius Medical Care AG&Co.KGaA(紐約證券交易所代碼:FMS-GET Rating)已經獲得了目前覆蓋該公司的14家經紀公司的一致建議,即“持有”。八名投資分析師對該股的評級為持有,兩名分析師對該公司的評級為買入。在過去一年對該股進行評級的券商中,12個月目標價的平均水平為45.83美元。

A number of equities research analysts recently weighed in on the company. DZ Bank downgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research report on Friday, July 29th. JPMorgan Chase & Co. dropped their price objective on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. Berenberg Bank dropped their price objective on Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a research report on Wednesday, August 10th. Finally, Truist Financial lowered their price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd.

一些股票研究分析師最近對該公司進行了分析。DZ銀行在7月29日星期五的一份研究報告中將Fresenius Medical Care AG&Co.KGaA的評級從“買入”下調至“持有”。摩根大通(JPMorgan Chase&Co.)在8月1日週一的一份研究報告中將費森尤斯醫療保健公司(Fresenius Medical Care AG&Co.KGaA)的目標股價從51.00歐元下調至23.00歐元(23.47美元)。7月29日,瑞銀集團在一份研究報告中將Fresenius Medical Care AG&Co.KGaA的評級從買入下調至中性。貝倫貝格銀行在8月10日星期三的一份研究報告中將Fresenius Medical Care AG&Co.KGaA的目標價格從76.70歐元(78.27美元)下調至57.95歐元(59.13美元)。最後,Truist Financial在6月22日星期三的一份報告中將Fresenius Medical Care AG&Co.KGaA的目標價從34.00美元下調至27.00美元,並將該公司的評級設定為持有。

Get
到達
Fresenius Medical Care AG & Co. KGaA
費森尤斯醫療保健股份公司
alerts:
警報:

Institutional Inflows and Outflows

機構資金流入和流出

Several institutional investors have recently modified their holdings of the company. SRS Capital Advisors Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company's stock worth $52,000 after purchasing an additional 409 shares during the last quarter. Signaturefd LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company's stock worth $74,000 after purchasing an additional 458 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 53,824 shares of the company's stock worth $1,747,000 after purchasing an additional 516 shares during the last quarter. Timber Creek Capital Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 0.3% in the second quarter. Timber Creek Capital Management LLC now owns 199,285 shares of the company's stock worth $4,970,000 after purchasing an additional 542 shares during the last quarter. Finally, Wetherby Asset Management Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 9.0% in the first quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company's stock worth $229,000 after purchasing an additional 560 shares during the last quarter. 5.59% of the stock is currently owned by hedge funds and other institutional investors.

幾家機構投資者最近調整了對該公司的持股。SRS Capital Advisors Inc.第一季度增持了費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)36.0%的股份。SRS Capital Advisors Inc.現在持有1,545股該公司股票,價值52,000美元,該公司在上個季度又購買了409股。Signaturefd LLC在第一季度將其在Fresenius Medical Care AG&Co.KGaA的持股增加了26.4%。Signaturefd LLC在上個季度額外購買了458股後,現在擁有2190股該公司股票,價值7.4萬美元。Dimenius Fund Advisors LP在第四季度將其在費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股份增加了1.0%。Dimension Fund Advisors LP在上個季度額外購買了516股後,現在擁有53,824股該公司股票,價值1,747,000美元。Wood Creek Capital Management LLC在第二季度增持了費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)0.3%的股份。Wood Creek Capital Management LLC現在擁有199,285股該公司的股票,價值497萬美元,上個季度又購買了542股。最後,Wetherby Asset Management Inc.在第一季度增持了費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)9.0%的股份。Wetherby Asset Management Inc.在上個季度又購買了560股後,現在持有6,807股該公司股票,價值22.9萬美元。5.59%的股票目前由對衝基金和其他機構投資者持有。

Fresenius Medical Care AG & Co. KGaA Price Performance

費森尤斯醫療保健股份公司KGaA價格表現

FMS opened at $16.67 on Monday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $16.06 and a 12-month high of $36.84. The business's fifty day simple moving average is $19.14 and its 200-day simple moving average is $26.28. The company has a market capitalization of $9.77 billion, a price-to-earnings ratio of 10.62, a PEG ratio of 0.84 and a beta of 1.03. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.
FMS週一開盤報16.67美元。費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股價為16.06美元,為12個月低點,12個月高位為36.84美元。該業務的50日簡單移動均線切入位為19.14美元,200日簡單移動均線切入位為26.28美元。該公司市值為97.7億美元,市盈率為10.62倍,市盈率為0.84倍,貝塔係數為1.03。該公司的流動比率為1.18,速動比率為0.85,債務權益比率為0.47。

About Fresenius Medical Care AG & Co. KGaA

關於費森尤斯醫療保健股份公司

(Get Rating)

(獲取評級)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Fresenius Medical Care AG&Co KGaA在德國、北美和國際上提供透析護理和相關的透析護理服務。它通過門診透析診所網絡提供透析治療以及相關的實驗室和診斷服務;材料、培訓和患者支持服務,包括臨牀監測、後續援助和安排將用品運送到患者住所;以及根據合同向美國醫院提供為住院的終末期腎病(ESRD)患者和急性腎功能衰竭患者提供的透析服務。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
  • Kroger's is Your One-Stop Consumer Staples Stock
  • Adobe Perfects the Art of the Faceplant for Investors
  • Tax Credits are the Incentives in the Inflation Reduction Act
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • 3 Banks Worth Considering For Q4
  • 免費獲取StockNews.com關於Fresenius Medical Care AG&Co.KGaA(FMS)的研究報告。
  • 克羅格百貨是你的一站式消費者史泰博股票
  • Adobe為投資者完善Facebook工廠的藝術
  • 税收抵免是《降低通貨膨脹法案》中的激勵措施
  • 股市:紅海中的三座強國
  • 第四季度值得考慮的3家銀行

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

接受Fresenius Medical Care AG&Co.KGaA Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fresenius Medical Care AG&Co.KGaA和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論